ClinicalTrials.gg

Program

zemprocitinib

Also written as “LNK01001”, “LNK01001 Dose A” and “LNK01001 Dose B”.

Its studies are mostly in Arthritis, Rheumatoid · Spondylitis, Ankylosing · Dermatitis, Atopic, led by Lynk Pharmaceuticals.

Furthest: phase 3, since Feb 2, 20246 company-led studies, 1 open or runningNext primary completion: Nov 2026 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Lynk Pharmaceuticals61 open or runningphase 3since Feb 2, 2024Oct 10, 2023Nov 2026phase 3 · NCT07237568

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 10, 2023First studies: 3 phase 2 studiesFirst studyNCT06099535, NCT06085534, NCT06085521
  2. Feb 2, 20242 phase 3 studiesNCT06277245, NCT06276998
  3. Nov 16, 2025Phase 3 study in Spondylitis, AnkylosingNCT07237568 · 352 planned · China

Ahead

  1. Nov 2026Primary completion: phase 3 study in Spondylitis, AnkylosingNCT07237568

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 6 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07237568Spondylitis, Ankylosing · China3RecruitingNov 2026352
NCT06277245Dermatitis, Atopic · China3CompletedApr 18, 2025356
NCT06276998Arthritis, Rheumatoid · China3CompletedAug 22, 2025430
NCT06099535Arthritis, Rheumatoid · China2CompletedDec 29, 2022156
NCT06085534Spondylitis, Ankylosing · China2CompletedDec 6, 2022177
NCT06085521Dermatitis, Atopic · China2CompletedJun 14, 2023150

How it is read

Names in the registry

  • “LNK01001”, 4 entries
  • “LNK01001 Dose A”, 2 entries
  • “LNK01001 Dose B”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
zemprocitinib (Lynk Pharmaceuticals): development program | ClinicalTrials.gg